Jacqualyn Fouse Biography and Net Worth

Director of Agios Pharmaceuticals

Dr. Fouse has served as a member of our board of directors since December 2017 and as board chair since August 2022. She served as chief executive officer of Agios from February 2019 to August 2022. She previously served as president and chief operating officer of Celgene Corporation until April 2017, and as a member of Celgene’s board of directors through June 2017. Dr. Fouse joined Celgene in 2010 as chief financial officer and was named president of the company’s global hematology & oncology franchise in 2014. Before joining Celgene, Dr. Fouse served as chief financial officer of Bunge Limited, a leading global agribusiness and food company. Prior to Bunge, she served as senior vice president, chief financial officer, and head of corporate strategy at Alcon Laboratories, a leading ophthalmic pharmaceutical and medical device company. Prior to her tenure with Alcon, she held a variety of senior leadership roles with international companies, spending almost a decade of her career in Switzerland. Dr. Fouse also serves on the board of directors of Incyte Corporation. Dr. Fouse earned her B.A. and M.A. in economics and a Ph.D. in finance from the University of Texas at Arlington.

What is Jacqualyn A. Fouse's net worth?: The estimated net worth of Jacqualyn A. Fouse is at least $5.77 million as of April 10th, 2024. Dr. Fouse owns 137,396 shares of Agios Pharmaceuticals stock worth more than $5,765,136 as of December 18th. This net worth estimate does not reflect any other investments that Dr. Fouse may own. Learn More about Jacqualyn A. Fouse's net worth.
How do I contact Jacqualyn A. Fouse?: The corporate mailing address for Dr. Fouse and other Agios Pharmaceuticals executives is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. Agios Pharmaceuticals can also be reached via phone at (617) 649-8600 and via email at [email protected]. Learn More on Jacqualyn A. Fouse's contact information.
Has Jacqualyn A. Fouse been buying or selling shares of Agios Pharmaceuticals?: Jacqualyn A. Fouse has not been actively trading shares of Agios Pharmaceuticals over the course of the past ninety days. Most recently, Jacqualyn A. Fouse sold 7,791 shares of the business's stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $27.55, for a transaction totalling $214,642.05. Following the completion of the sale, the director now directly owns 137,396 shares of the company's stock, valued at $3,785,259.80. Learn More on Jacqualyn A. Fouse's trading history.
Who are Agios Pharmaceuticals' active insiders?: Agios Pharmaceuticals' insider roster includes Carman Alenson (Insider), Jonathan Biller (CFO & Head of Corp. Affairs ), Christopher Bowden (Insider), James Burns (https://www.linkedin.com/in/jackie-fouse-a90b811aa), Jacqualyn Fouse (CEO & Director ), Jacqualyn Fouse (Director), Sarah Gheuens (Chief Medical Officer, Head of R&D), Brian Goff (CEO), Cecilia Jones (CFO), and Darrin Miles (Insider). Learn More on Agios Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Agios Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 17 times. They sold a total of 76,341 shares worth more than $2,120,143.90. The most recent insider tranaction occured on December, 11th when Director David Scadden sold 200 shares worth more than $9,256.00. Insiders at Agios Pharmaceuticals own 4.9% of the company. Learn More about insider trades at Agios Pharmaceuticals.
Information on this page was last updated on 12/11/2024.

Jacqualyn A. Fouse Insider Trading History at Agios Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/10/2024	Sell	7,791	$27.55	$214,642.05	137,396
1/24/2024	Sell	10,722	$21.64	$232,024.08	129,253
1/9/2024	Sell	8,391	$22.99	$192,909.09	116,075
6/30/2023	Sell	10,718	$28.36	$303,962.48	106,966
11/13/2019	Buy	40,322	$31.00	$1,249,982.00	41,722

Jacqualyn A. Fouse Buying and Selling Activity at Agios Pharmaceuticals

Agios Pharmaceuticals Company Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $41.51

$40.50

$42.28

50 Day Range

MA: $50.09

$38.17

$61.64

2 Week Range

Now: $41.51

$20.96

$62.58

Volume

237,904 shs

Average Volume

719,033 shs

Market Capitalization

$2.37 billion

P/E Ratio

3.69

Dividend Yield

N/A

Beta

0.8

This drone stock is setting up to transform medical supply delivery

From The Tomorrow Investor | Ad

Drone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.

Click here to see how a new partnership could catapult this drone suppliers' growth